Search for Clinical Trial Results

Sponsored By

Chromosome 17p Deletion - 12 Studies Found

Status Study
Completed Study Name: A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Condition:
  • Chronic Lymphocytic Leukemia With 17p Deletion
  • Small Lymphocyti
    Date: 2012-12-03
    Interventions: Drug: Ibrutinib All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
Terminated Study Name: Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Condition: B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
Date: 2014-01-22
Interventions:
  • Drug: Idelalisib 150 mg tablet
Active, not recruiting Study Name: A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion
Condition:
  • Chronic Lymphocytic Leukemia
  • 17 p Deletion
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Date: 2014-11-19
Interventions:
  • Drug: acalabrutinib Patients u
Recruiting Study Name: Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Condition:
  • CLL
  • SLL

Date: 2011-10-18
Interventions:
  • Drug: Ofatumumab 1000 mg IV
Recruiting Study Name: Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine
Condition: Chronic Lymphocytic Leukemia
Date: 2011-06-28
Interventions: Drug: Alemtuzumab Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
Recruiting Study Name: A Study Evaluating Venetoclax in Subjects With Chronic Lymphocytic Leukemia Whose Cancer Has Come Back or Who Had No Response to Previous Cancer Treatments Including Subjects Missing Part of Their Chromosome 17, or TP53 Gene Mutation; or Who Received Prior Treatment With a B-Cell Receptor Inhibitor
Condition: Chronic Lymphocytic Leukemia (CLL)
Date: 2016-11-30
Interventions: Drug: Venetoclax Tablet Other Name: ABT-199
Completed Study Name: Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Date: 2013-12-03
Interventions: Drug: Ruxolitinib 20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progres
Next >>>